January 25, 2012
AnGes MG, Inc.
Dr. Gavin James Murphy at Bristol Heart Institute, Bristol
University had submitted the application for "Novel and
Emerging Technology Grant" with a project titled, "The effect
of periadventitial injection of naked plasmid DNA encoding
human hepatocyte growth factor on the progression of vein
graft disease." AnGes MG is pleased to announce that Dr.
Murphy's project was adopted for the above mentioned
grant.
The purpose of "Novel and Emerging Technology Grant" is to
fund medical research projects focusing on the development of
new technologies to prevent and treat heart disease in the
UK. Being adopted for this grant indicates that it was
recognized as a superior scientific technology and therefore,
it is likely that HGF gene treatment will be drawing much
attention in the medical community in the UK.
Dr. Murphy believes that graft adventitial neoangiogenesis is
an effective method that leads to long term patency of venous
graft, and plans to evaluate HGF's neoangiogenesis function
for the prevention of vein graft disease in this project.
AnGes MG will give its full corporation on this project by
providing "Collategene," a therapeutic agent for ischemic
diseases.
AnGes MG is currently preparing for a global clinical phase
III study on "Collategene."
Meanwhile, this trend will have no effect on the business
performance for the fiscal year of
2012.
[Reference]
Vein graft disease
Venous vessel (vein graft) is used as a bypass in coronary-artery bypass surgery. In some cases, arteriosclerotic lesions, such as thrombosis and thickening of the vessel wall, progress due to angiopathy and hypertensive aorta during the surgery. This progression can lead to vascular stenosis and occlusion, which is called vein graft disease.
distribué par | Ce noodl a été diffusé par AnGes MG Inc. et initialement mise en ligne sur le site http://www.anges-mg.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-25 07:42:25 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
An Academic Research using “Collategene,” a Treatment Agent for Ischemic Disease was Adopted for a Grant in the UK - A Research on HGF Gene Therapy for Venous Graft Disease by Bristol University - |